STOCKS TELEGRAPH

Tag: IM Cannabis

  • 3 Stocks Catching Investor Interest: IM Cannabis (IMCC), Zhengye Biotechnology (ZYBT), Cardiol Therapeutics (CRDL)

    3 Stocks Catching Investor Interest: IM Cannabis (IMCC), Zhengye Biotechnology (ZYBT), Cardiol Therapeutics (CRDL)

    Innovation continues to be a major driver of value creation in the biotech and healthcare industries, where companies are racing to develop next-generation therapies. Firms that demonstrate both scientific progress and commercial potential are increasingly capturing investor interest. Recent trends suggest that several stocks are beginning to align these factors effectively.

    IM Cannabis Corp (IMCC)

    IM Cannabis Corp (NASDAQ: IMCC) opened the trading on April 10, 2026, with great promise as it jumped 1.66% to $0.36. During the day, the stock rose to $0.36 and sunk to $0.34. Taking a more long-term approach, IMCC posted a 52-week range of $0.29-$7.12.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 43.53%. Meanwhile, its Annual Earning per share during the time was 43.53%. This publicly-traded company’s shares outstanding now amounts to $5.89 million, simultaneously with a float of $1.71 million. The organization now has a market capitalization sitting at $2.25 million.

    Zhengye Biotechnology Holding Ltd (ZYBT)

    Zhengye Biotechnology Holding Ltd (NASDAQ: ZYBT) started the day on April 10, 2026, with a price increase of 7.07% at $1.06. During the day, the stock rose to $1.06 and sunk to $0.97. Taking a more long-term approach, ZYBT posted a 52-week range of $0.68-$14.30.

    This publicly-traded company’s shares outstanding now amounts to $47.39 million, simultaneously with a float of $4.43 million. The organization now has a market capitalization sitting at $50.23 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is advancing its clinical pipeline with a focus on generating meaningful data that supports disease modification in cardiovascular conditions. The company’s work in acute myocarditis highlights its potential to address not only inflammation but also structural damage to the heart.

    Market Momentum

    As of April 10, 2026, CRDL closed at $1.38, unchanged from the previous close, with trading volume (446,875 shares) below its average of 588,345 shares—suggesting a period of consolidation. With a market cap of $154.119M, the stock remains near the upper end of its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.44 continues to reflect strong upside potential tied to clinical progress.

    Clinical Evidence: ARCHER Trial

    The completed Phase II ARCHER study evaluated CardiolRx™ in patients with acute myocarditis, a condition that can lead to heart failure or sudden cardiac complications. Results demonstrated significant reductions in left ventricular (LV) mass, an important marker of cardiac remodeling and disease severity. These findings suggest that the therapy may contribute to structural recovery, not just inflammation control.

    Clinical Significance

    The observed improvements in cardiac structure are particularly notable given the limited treatment options available for myocarditis. By showing potential to reverse aspects of disease progression, CardiolRx™ may represent a shift toward therapies that actively repair cardiac damage.

    Outlook

    If these findings are validated in future studies, Cardiol could expand its clinical footprint beyond pericarditis into broader inflammatory heart diseases, strengthening its long-term growth profile.

  • IM Cannabis Corp. (IMCC) stock had a GOOD Friday, but why?

    IM Cannabis Corp. (IMCC) shares soared 6.54% in after-hours on Friday, July 2, 2021, and closed the weekly trading at $5.70 per share. Earlier, IMCC’s stock gained 5.31% to close Friday’s normal session at $5.35. IMCC shares have moved up by 5.52% in the past week. Over the past three months, the stock has lost 29.61%, while over the past six months, it has declined 27.70%.

    Let’s see what’s going on recently with IMCC?

    Participation in the recent conference

    IM Cannabis Corp recently participated in the Cannabis Industry Virtual investor conference which held on Tuesday, June 29, 2021.

    The presentations from the June 29th & 30th Cannabis industry virtual investor conference are now available for on-demand viewing at VirtualInvestorConferences.com.

    Update about the proposed acquisition of MYM

    On June 28, 2021, IM Cannabis Corp announced that Glass, Lewis & Coand Institutional Shareholder Services Inc have each issued positive recommendations of IMC’s proposed acquisition of MYM Nutraceuticals Inc.

    The high effectiveness of seven IMC-branded medical cannabis strains proved

    On June 17, 2021, IM Cannabis Corp released its proprietary data from a clinical survey evaluating medicinal cannabis therapy. The patient survey reported the high effectiveness of seven IMC-branded medical cannabis strains in treating and alleviating symptoms of seven key health conditions in a clinical group of Israeli participants. The survey data will be used to help patients and doctors in medical markets all over the world customize cannabis-based therapies to best treat their diagnoses.

    Supply Agreement with Canadian LP the Flowr Corporation

    On June 7, 2021, IM Cannabis Corp announced that Focus Medical Herbs Ltd. (“Focus Medical”) has signed a multi-year supply agreement with The Flowr Corporation.

    Focus Medical will import Flowr’s ultra-premium cannabis strains into Israel according to a three-year supply agreement. This new partnership with Flowr strengthens and further contributes to IMC’s new indoor ultra-premium product category under the IMC brand.IM Cannabis Corp has an exclusive commercial agreement with Focus Medical in Israel.

    First Closing of the Panaxia Acquisition

    On June 1, 2021, IM Cannabis Corp provided an update about the acquisition of Panaxia.

    On April 30, 2021, IMC Holdings Ltd which is the Company’s fully owned Israeli subsidiary, signed a definitive agreement with Panaxia Pharmaceutical Industries Israel Ltd. and Panaxia Logistics Ltd.

    The company has now done the first closing and the second closing is expected to occur before July 30, 2021, or upon receipt of the Israeli Ministry of Health approval.

    Conclusion

    Though we do not have any recent development about IMCC as we know the cannabis industry is progressing very well and that’s the reason behind IMCC good performance before the long weekend. We can expect it to continue its positive performance after the long weekend as well.